0001193125-23-059077.txt : 20230303 0001193125-23-059077.hdr.sgml : 20230303 20230303083057 ACCESSION NUMBER: 0001193125-23-059077 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230302 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230303 DATE AS OF CHANGE: 20230303 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aadi Bioscience, Inc. CENTRAL INDEX KEY: 0001422142 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 611547850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38560 FILM NUMBER: 23701740 BUSINESS ADDRESS: STREET 1: 17383 SUNSET AVENUE STREET 2: SUITE A250 CITY: PACIFIC PALISADES STATE: CA ZIP: 90272 BUSINESS PHONE: 424-473-8055 MAIL ADDRESS: STREET 1: 17383 SUNSET AVENUE STREET 2: SUITE A250 CITY: PACIFIC PALISADES STATE: CA ZIP: 90272 FORMER COMPANY: FORMER CONFORMED NAME: Aerpio Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20170316 FORMER COMPANY: FORMER CONFORMED NAME: ZETA ACQUISITION CORP II DATE OF NAME CHANGE: 20071227 8-K 1 d377824d8k.htm 8-K 8-K
false 0001422142 0001422142 2023-03-02 2023-03-02

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 2, 2023

 

 

AADI BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38560   61-1547850

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

17383 Sunset Boulevard, Suite A250

Pacific Palisades, California

   90272
(Address of principal executive offices)   (Zip code)

Registrant’s telephone number, including area code: (424) 744-8055

 

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share   AADI   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of President, Chief Executive Officer and Director

On March 2, 2023, Brendan Delaney submitted a letter to the Board of Directors (the “Board”) of Aadi Bioscience, Inc. (the “Company”) resigning from his position as the Company’s President and Chief Executive Officer (“CEO”) and as a member of the Board of Directors, effective March 14, 2023. Mr. Delaney’s decision to resign was not the result of any disagreement with management or the Board, or related to the Company’s operations, policies, or practices.

Appointment of Interim Chief Executive Officer

Effective March 15, 2023, the Board appointed Scott Giacobello, the Company’s Chief Financial Officer, to serve as the Company’s Interim CEO and President and principal executive officer. Mr. Giacobello will continue to serve in his role as Chief Financial Officer in addition to his role as Interim CEO and President. In addition, Neil Desai, Ph.D., the founder of the Company and its President and CEO prior to Mr. Delaney, continues to serve as the Executive Chairman and a member of the Board and will assist with the leadership transition. The Board has also initiated an executive search for a successor CEO, and, as such, Mr. Giacobello’s position of Interim CEO and President will end when a successor is appointed.

As of the filing of this Current Report on Form 8-K (this “Report”), the Compensation Committee of the Board and the Board have not finalized the compensation of Mr. Giacobello in connection with his appointment as Interim CEO and President. The Company will provide this information by filing an amendment to this Report after the information is determined or becomes available.

Biographical information for Mr. Giacobello can be found in the Company’s definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on April 26, 2022, and is incorporated herein by reference.

Mr. Giacobello purchased 20,000 shares of the Company’s common stock (for a purchase price of $250,000) in a private placement transaction that closed on September 26, 2022 (the “PIPE Financing”). Mr. Giacobello’s transaction was on the same terms as the other investors who purchased shares in the PIPE Financing pursuant to the Securities Purchase Agreement dated September 22, 2022.

Other than the above PIPE Financing, Mr. Giacobello has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K promulgated under the Securities Exchange Act of 1934, as amended, nor are any such transactions currently proposed. There is no arrangement or understanding between Mr. Giacobello or any other person pursuant to which Mr. Giacobello was selected as an officer. There are no family relationships between Mr. Giacobello and any of the Company’s directors or executive officers.

 

Item 7.01

Regulation FD Disclosure.

On March 3, 2023, the Company issued a press release announcing Mr. Giacobello’s appointment as Interim CEO and President. The press release is attached hereto as Exhibit 99.1 and incorporated into this Item 7.01 by reference.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

Number

   

Description

99.1    Aadi Bioscience, Inc. Press Release dated March 3, 2023
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: March 3, 2023      
     

/s/ Stephen Rodin

      Stephen Rodin
      Secretary, Senior Vice President and General Counsel
 EX-99.1 2 d377824dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Aadi Bioscience Announces Leadership Transition

LOS ANGELES, CA, March 3, 2023 – Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Brendan Delaney has resigned for personal reasons from his position as Chief Executive Officer, President, and member of the Board of Directors of the Company. Scott Giacobello, currently the Company’s Chief Financial Officer, has been appointed to serve as Interim Chief Executive Officer and President in addition to his current responsibilities. In addition, Neil Desai, Ph.D., the Founder of Aadi Bioscience and its President and CEO prior to Mr. Delaney, continues to serve as the Executive Chairman and a member of the Board of directors and will assist with the leadership transition. The Board of Directors has initiated an executive search for a replacement CEO.

“Supported by a strong and experienced team, Aadi continues to drive forward the development of FYARRO nab-sirolimus in solid tumor patients with TSC1 and TSC2 inactivating mutations, as well as continuing to serve patients with PEComa. Mr. Giacobello has played a critical role in crafting our corporate and financial strategy and I look forward to his continued leadership as we conduct a search for a permanent CEO,” said Caley Castelein M.D., Chairman of the Board of Directors.

Mr. Giacobello said, “I look forward to my continued work with the Aadi board and management team, executing on our mission of developing FYARRO for significant unmet needs in oncology. We have a well-defined strategy and a strong financial position and are enthusiastic about the opportunities that lie ahead.”

Prior to joining Aadi in 2021, Mr. Giacobello’s background included fulfilling key financial and operational roles with a long history of leadership in commercial stage growth companies. He played a key role in the buildout of U.S. operations and commercial readiness in his role as CFO at GW Pharmaceuticals, leading the Company’s financial strategy and raising more than $620 million ahead of their acquisition by Jazz Pharmaceuticals in 2021. He had previously served as the CFO of Chase Pharmaceuticals prior to their acquisition by Allergan, where he served in executive roles in corporate finance and global research and development.

About Aadi Bioscience

Aadi is a commercial-stage biopharmaceutical company focused on precision therapies for genetically defined cancers to bring transformational therapies to cancer patients with mTOR pathway driver alterations. Aadi received FDA approval and has commercialized FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

Aadi has also initiated PRECISION 1, a Phase 2 tumor-agnostic registration-intended trial in mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 inactivating alterations. More information on the Company’s development pipeline is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain forward-looking statements regarding the business of Aadi Biosciences that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company’s current beliefs and expectations; anticipated future growth; the potential commercialization of FYARRO in the tumor agnostic oncology market; expectations regarding management performance following the leadership transition; and the Company’s potential as a commercial precision oncology company. Actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, those associated with uncertainties associated with the clinical development and regulatory approval of FYARRO in additional indications, including potential delays in the commencement, enrollment and completion of clinical trials for additional indications; the risk that unforeseen adverse reactions or side effects may occur in the course of commercializing, developing and testing FYARRO; and risks related to collaborations with third-parties.

Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in Aadi’s Quarterly Report on Form 10-Q filed November 9, 2022, and elsewhere in Aadi’s reports and other documents that Aadi has filed, or will file, with the SEC from time to time and available at www.sec.gov.

All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Aadi undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 199.

Contact:

Marcy Graham

IR@aadibio.com

###

EX-101.SCH 3 aadi-20230302.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 aadi-20230302_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 aadi-20230302_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g377824img001.jpg GRAPHIC begin 644 g377824img001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information
Mar. 02, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001422142
Document Type 8-K
Document Period End Date Mar. 02, 2023
Entity Registrant Name AADI BIOSCIENCE, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-38560
Entity Tax Identification Number 61-1547850
Entity Address, Address Line One 17383 Sunset Boulevard
Entity Address, Address Line Two Suite A250
Entity Address, City or Town Pacific Palisades
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90272
City Area Code (424)
Local Phone Number 744-8055
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol AADI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 d377824d8k_htm.xml IDEA: XBRL DOCUMENT 0001422142 2023-03-02 2023-03-02 false 0001422142 8-K 2023-03-02 AADI BIOSCIENCE, INC. DE 001-38560 61-1547850 17383 Sunset Boulevard Suite A250 Pacific Palisades CA 90272 (424) 744-8055 false false false false Common Stock, par value $0.0001 per share AADI NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.aadi.com//20230302/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d377824d8k.htm aadi-20230302.xsd aadi-20230302_lab.xml aadi-20230302_pre.xml d377824dex991.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d377824d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "d377824d8k.htm" ] }, "labelLink": { "local": [ "aadi-20230302_lab.xml" ] }, "presentationLink": { "local": [ "aadi-20230302_pre.xml" ] }, "schema": { "local": [ "aadi-20230302.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "aadi", "nsuri": "http://www.aadi.com/20230302", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d377824d8k.htm", "contextRef": "duration_2023-03-02_to_2023-03-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.aadi.com//20230302/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d377824d8k.htm", "contextRef": "duration_2023-03-02_to_2023-03-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aadi.com//20230302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aadi.com//20230302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aadi.com//20230302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aadi.com//20230302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aadi.com//20230302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aadi.com//20230302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aadi.com//20230302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aadi.com//20230302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aadi.com//20230302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aadi.com//20230302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aadi.com//20230302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aadi.com//20230302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aadi.com//20230302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aadi.com//20230302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aadi.com//20230302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aadi.com//20230302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aadi.com//20230302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aadi.com//20230302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aadi.com//20230302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aadi.com//20230302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aadi.com//20230302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aadi.com//20230302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aadi.com//20230302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001193125-23-059077-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-059077-xbrl.zip M4$L#!!0 ( -M#8U9D:'%S.@, #\+ 1 86%D:2TR,#(S,#,P,BYX M?-(G[^Y+";=HK-!J'*7)( )4N2Z$FH^CVL;< MYD)$[TZ?/SMY$<=P=GYQ!3'<.%?9C+&[N[NDF EEM:P=6;!)KDL&<=SI?[S^ M!G\WUC.8H$1N$4IN'1KX4 M99,/!<)BF@[?)FS[,(/?VH. .,QBQ$2.]$1QE MH[?9T9_PY3-\"D847(L2^TA=+8R8WSCX(W\) 72FE4(I<0'G0G&5"R[A:T?X M%5RH/('W4L+$PRRQM&ANL4A:J_>VR&Q^@R5__@R TJ5LILAD78XCGX,!)N&O5QL#V X&(P8]8*C'&,/(H7Z=P_" MBZ?4%GTG#R!WHP!(CX^/69!N4"K<>@2M]=>L$09M[IP1T]KAN3;E&FLZ[AN)FCN^(EVHKG>'":J9&VQ40T4_;/Y\NOH<>B M4P\ "&TGRDH;!TWW7>H\S,2>5/I?<5>!V%_%Z3 >I0D9BT!M9;RC?,">3*0K M[*.(++OB8")V5_?Z0^P/N[QO[_E'9V!SD'W\QS[^],U!\3]8!/\!$ZVNGDJF MM\T>7Q/%1=XLJ^9X>%U6R"?U9K<1?!Y>[W6\N4):K\$G5TJ[X*C/A%>54#/= M7M&E;^*LZ^0)SB"LKHR;W&B)^Q<1W3=SMF>^2 M3Q/:,YW* P?KX^7%C" H+U?T.JP3SH,OO1B\G%Y)+I>F?3N,(TMYE[WQ_)_# MK0S^;K@$L;390]EV1_VEI_7;P7L_UZ0!_O!MZUTN6@(GNF\ M]F]/]_U>%9\4T5I<4%>9,E"*0- K,B'U[P>I+PEV% ND_VLBM&XZ\!_Z.]=9 MZ!^Y*J Q!SU[)VS3R*;]VF+QESH-YYS+O);+A+?@5F,?<+-4AR-7S';CVMNN M6-T(L\T9;F_ZL]Y<-;N&?OX$4$L#!!0 ( -M#8U9#JL<8>P8 +A& 5 M 86%D:2TR,#(S,#,P,E]L86(N>&ULS9QO;]LV$,;?%^AWN'EO-J"R8[O8 M6J-ID3E)$2QI@L;=A@U#(4N,34PF#5*.[6\_4G\:.:9D*CQ5>=%6D>Z>NT?Y MGRXLY*>+P-*.R!CGX5^Q!DY[FR) M['QX__+%NQ\\#T[/+SZ!!_,X7LI1K[=>K[OA'6621ZM82M/]I9@FB*_U(/1C,H)A;]A3 M<4-X/1J^&;W^%6ZNX"P183"A"U+,Y,NMH+-Y##\%/T.2=,H9(U%$MG!.F<\" MZD=PFS?\"BY8T(63*(+/.DVJ+B41]R3L9JH19?^-]%]3W3N\? &@3B*3R;[C MCCX5V9G83$74Y6*F>CT:]O*4SD/&9B]E/4P2^F_?ONTE1XO1DIIBE7B_]]?5 MY6TP)PO?4R=??;."K(RD(YGLO^1!<@8M&H32"/V5EX=Y>I?7'WC#?G+M4\603$Q:23/F;-@^RJ+D@=ZFJ M1B^1E"3HSOA]+R14 S+0&Y[>T!W^J+[X.N:*]I.IC(4?Q+OU(GV*N,AW)B:. M.X:DWFY#.NY$!#M:O@AR';5YP'\6T0NX^KXM8R]1S-/O!%\8N\C*<K@)\[[<'O*:"A6-"2+Y2BB\ZGQK$S_O$V7X)]?^]UWOH?9S:55= M0B2YK-NO&Y(G"X6Y^A.?1_[,%LE'22TA:6Z=&PZZ(&D00D+RFS)H:6<@&VBT M"*1MMVXXGK&8QMNQ*B/\Z$)=@#>_DZTMEB7)+>%9;857!+G@6B&(A&U: ;(2 MD-0 5<09X 9;+X)$82!JD$0F]FT!*@: MH(N@X=M ZT:.K?O'6"Q\)C.J%\DL_N0OK(DVY[:Z5"@QPLMCW!<*)CW<=<)# M!= ED%8)3?1M6"18-X\!\@4+N%ARD=PJN8W5X(SY2BU2MF,>UN3Z@%2KF-O9 MY-8I[D-@(8\[$SL%(:D(64G0-9&&Y#OX,LS,T\UA#-$YC:U M.AX& ]Q\W!W\QUJXE&MU2.61@,;NUT"O5=,8H$[\S46H%DOTCJ8WQY]";:E( MJP@?LL8M@MWAKA3&)5V5@MU:N-PW:L4P!$_P@S$2)V&H#,CLGTO*2+_>.!@% M6AV%*DO\0*#[")2*XN*?Z;_*-T!7@FN&M8YIS(8!_2=X:0;]@2OZ@V>'_L 6 M_4$3Z ^^'_J3-6\,?20;UNA7>D%$?ZPVK\6$K]F3P"^F/P?L#79,T#^$H2'_ M6+(AX'49X )T(5S8L0U4H6[G A'SY.?A:W$C^#UE0!'ENMV[X7S+(QK0F++9E5IQ"^I'MBR;,EL"N<($ M+XMP0;A,#8G?!WG(]9WA;:KE(KFU^G;#]D80/1]$89&\":D_'2.N[^[L%PY5 M"BUA;&&*'XITP?J0*A+>J@P4ZT!:"))*SJ W;:((_!.=H*)_(>6*"/AKUXQ)$HT6YJ,-)RC#FXT[+&J,6UJ(F$P>E#HF\^YJFD7YW5C0UFG8#=2)\_4GSV^UB MRJV7X(^26D+4W#HW''2!TR"$1&:F#*FT,Y4--%I$TK9;G.OFV2:8*[>DSH<9 MS+DM7S^-1GAY#,9U=%\/^UJ:5\#Y,$-S?1NOJ9;-8SS?.UL0,5-3\U'P=3Q7 MBY&ESVI^D+=$HM4G?-6V^,%0]V=\%;)(K&\MEZ M*>ZX5%OZ5ZYDNVCZBT?4GO\!4$L#!!0 ( -M#8U;%7<[CO 0 #8L 5 M 86%D:2TR,#(S,#,P,E]P&ULU9I=<^(V%(;O=V;_@^K>M#,UYB.[ MFS A.Y0D':8D88!M.[W9$?8!-)4E1A(!_GV/#&HQF"QDMQTK%P%LO4?O.8\0 MENSKCZN4DV=0FDG1"FJ5:D! Q#)A8MH*%CJD.F8L(-I0D5 N!;2"->C@X\W; M-]??A2&YO>\^DI#,C)GK9A0ME\M*,F%"2[XP&%)78IE&) Q=^\[H$_EMTUV3 M#( #U4!2J@TH\O."\:19K];KM5KULO)^5Z: VG@DH0::I!$U(FS7(!?-QF7S MX@/I/Y"[+(@@(Y;"KE+.UXI-9X;\$/](,M&M% (XAS6Y9X**F%%.AL[P3Z0K MX@II M5^@F,?^H=\V]BS8G77O-FCJ+U)-Q5OD3TB)'6]A/H6L6VD-AK1XV:I653H(; MV^6FJDIR&,"$V-=/@VZN3TH3EHVFC'RU4:U'AJZDD.DZLNVC6QDO4A#&O;9% MLC'/9N^]LADI#7)G*YR@! M9GNLVS>V-)NRX(?/'8G31'NLC:*QR:?/[1B1RAWD= R\%12(HF]IJ(UI)S;U M>TZGIQK:$^4-[2)KJS@7DJK8A<.W![SRXWW;(II3A?'">(83FU-/E$P+B[/M M318:E2H!U0HP??R>!V2NF%0(&X\$9*'1BYQ;UY3;2BNO*2^D MO$_'YIUW;/J 7G&Z3V[Q:NA<2'OB\M/:,^RPO?<&VV9N&,"4V42%>:3IR=2* MM>6%5NS7,?O@&3-<"D@UERHK[1 K#!VYP"E^W9')F0B_$*KL1+]@WP&^] SP M/>/PN$C'H,ZCN:LK.[I=KX[3E6><1G353; ,;,(VR]'70#L:I.P$CQK?XFQ4 M/A+ Q0=HR%IAW"FO<(ZU^+L.XCPOJ_"'U;FV^SZ.#; M)S622_$J@+MR3_#M6G;P_%FAYU+)+L6>5%_)9V:W>U]#\""&)Q@/?#N6%WZR M[$MM*/^3S<]?711'\(3CGFM'T9]]&3N?M!70<[CE->4EE??IV/BS^6+O7_'^ M3(HSUWF'NO(R.O3J./FSX?([^C,@.C)-%V*[S-&GPCHB+B^Q(X8=-G^V48:2 MLY@9)J8/^&.LF+5V&K,B97F!%;EUM/S93.DKL$,.\&HINP]B[T&KI\GD]&GQ MI0CEI?>2ZRW%"W_V4/:RZ6J] /7U+ OB>$.TP+OCZL_&RA#BA;58JX]'S/"3 M+R4/=>7E=NC5/S9'W%#[&X5SZB8 MPCFW6XNUY855[-.1O4$L#!!0 ( -M#8U9>3N%2CA, !5Z M . 9#,W-S@R-&0X:RYH=&WM'6MSXD;R>ZKR'Z;(Y0I7\13XA1]77LSN M4=FU7>#Y+:I &,UFAT,)"00-F",=Q-O);N">?7TNWMZQ/D_ MIF.7/#*IN/ N"O5*K4"89PN'>P\7A3 8ED\*Y!^7/_YP/@J@(W3V5,MA_*(P M"@*_5:U.!]*M*&97'L1C%1JJ5LVR"E''4)6#F<]4TGM(U: BY$,U;LET]X3G MA>.D\V0RJ>CI<8 3R"J.J$*G,O1BDMOQN*G+O:^989.&'E0_/3VMZM:XZU+/ M9 &K5FM4L7E %8N[4^KP3'?\HF*+,<+=J#5J">Q3Q?,@@%GKU=^^?.[;(S:F M9>ZI@'IV,G\8R)70G%:A->[(E6A:]>,G0(]Z) .FJ_K6H:\'&V6_?>A]GGF^>DW*@GN(3%^5-; M7< BMCH++!EU/JJ:QJCK:B9!]BYH/F?4P7\#'KCL\J3\RWG5/,)W8Q90@C.4 MV7]#_GA1: LO8%Y0O@?.+!#;?+HH!&P:5/6,I(KCJM&DA)#S@7!FE^<.?R0J MF+GLHN!PY;MTAMS/"I?DG$];V)W)Z)D[#O/,,W2Y,:Q//#K&L8RWKL;,<^#_ MX*-+'R(@ID&/#:$YE!K'OR.WEFOPG_5[(%*?"I=#ZBIV7LU,OK08=RX*_]1P M_ XK_M[Q ".S-BPIJ=OU'#;]A<529NOS!:]FP%R8+V?8)=X)1ZZ1RR+VS5%^7 M#8.S,94/W"OC7Z] MZ=YWKDG__NJ^TU\-3FU/X/0[[5][W?MNIT^N;JY)Y[?V/Z]N/G5(^_;+EVZ_ MW[V]>1&,UBY@_#=5(W ! ^&5R'6E72%6[;!YN@!7:M%U.#/+$,])5"YG'FW% MF94:=,LRYYF14JO^\_+NUY32^69B)9%'L/J^N.KC;>\+.5<^]1)%-.(!*\,W M-@/C.9'4!V.RRHNX%G:(3D3*DUG?4FLO*6NBSZL(RN4[Q[P*Q^Q$QD$+]3HW M]Z37N;OMW;^]SKD+I0JI%Y! D#ZSD><,QNH-(B2I'Q:=@[>'4@Q),&((8"AY MP&%\9VJ/J/? R)4=$&BNGS::J^'<&WG1_4%P>LP7,B#%^#.CX/XP%1#V"#V) MU,W,.6BM#C%BY7"G?:B.<:TVU1+$A'P7!0@36PY,,(;A(X?.9@ 1\PJ77\#? M'AF*6R6"(Y>5RKLVV;TVL9J[8+?5W&.BP1Y[X I#_^ &6C8V,5=7UUWRH7O; M;W<[-^U.B71OVI6&7L%8[\$,9C3H0.7$9NY+GI%.L59*^C//G6<^'.T5K176[@N M]15KQ0]/\TB*H="M,]BHUVH_1[AKU2(P6[4XVD/ I/G'R0:1C>;/&/\'SD+K M(Y,!MZD;8==L.+=G-(^UP3PQS/E#%B>$OR+89=S%IP^L/)",?L5\)W=8BSX* MX)"U$5?7I,NN2U+<1#+LU-*,1!;V CP!$*;=X47I?<(9-AJKZ]E"@G'4JJD? M@,5JB] +Y*PMG!=9/TR28C(C8+X4C[@LFK]KYM()6,*5GO2Z;!#S_%+_5\'A MUA&'0?)'[C)H&X!NVCP_6"\W3@Z/:BLQ]F=&W#V==J/LFJTQM246C^KE^F'S M^.1P'32^AK2?[$C8M[7[.XF^BUH_8)@B(#J0Y \(#I3#=1"SD5-2?P7@P _A M:5UV8&SKVXC%VY*I+<9CKM2W0!74?,0([5^8(-U*K]*OD,[8=\6,R3>G2E:G MDAM1F1-':S_X"[W([]8KU2"^S"T]K.W8G6R>?.ON9"QZ;QM(7%EY MGLGV6F*?E&C#XZV\%Q-OX\W?40:3!=Y3E[ IL\. /V+V"_B7J8-O.PPK FF!J@X[6")+CJ7?,(^_$U4S M3YS^_:<3JWY\I@ /+O-'PF/$T_YC"?U[-T1?@5#@'+VA)_+YJ)>NH-]6/%UL M6LV#Y;Y9/:X>$>CB"W9(3=N,H?01-#:&E2RU(K M9OA(C10""PR).8<">4%-3URJXN.=RGN&^74.8I^3<#"/(V9_U4>&U >S"9H2 M$P4#,24#YHH)D@T;D;C/"Y$^:-=<38;<17'G"F0_8)X#9 \$4'X M.MHZ^MEI=).$-/,P9SF>6HBWUC/"BW8U"E]^/LNU/*LTWK\E#X!DF(L(O2C2 M5"]VS 9"N ,*Y J N1#+IZ 8SY:5XG-F>#$I0+(4)2\V>@M%<87+"!^ @#1" MB)^J!^A!($*:UF'$H0LG\'CP7JP?D_;''K$:M0ITW"1J?V?;M=BV#UK8!H1[ M#U] A8$><__"/#M'!DQML+',L,_J\WJ3ENM6K-+GO)TI*8DY^]G9K&:M8F8\ M2/D^[T*P2R&XDPSU-A9>ZW(YM+SR=CCHJ%3+Y+DIO+$H-5FX6[=V*4C3GVJ*T\_ KY26: M.(=)B)3\E:6F*/AQ\ /;71WK? ='/>\%2'O,H*Z1N%BQVQS9>=,CT'N\[F@J MA>T1L5VJU+XR^=LB\8U/L>\E1>%]\\/K_FP,346UMWJ"[Y1>-U%UKF9P%EFW M-Z>>\ CH H!H;JBR]O(;/!=_)F-@C.^L;@VT4MDXM8]>(J"E'PC[:XGX5))' MZH:,_*U6PEBP(4D.U<$/&=PWG'1!_(@Q208H?_N8^*=*N*P(??,)0&3]ZP=DN5K1_/; M1@U21!(?G^G<9]R9Z^L%/EXOP..B-8, :U!.\E'K775Z?M(8.@P(EN9/@5EY MV:VIY^G4R<>YD8](2IZN"HAG^*0G:)OQ>PM77Q<[W>$3?(E'S+E,SI<.D4; MPLR%J I8V!,ZQ@H5T[T 1]%1%;X#A.M3*',Q'W&BUW)GN/B$P](H#A[ !RV2 M/7(%XT PJ&=CLI7:-E;C8V=\&XA#I:/,(97S9(#7*-(DP$NS(DQ\:N4\S)@0'IP7MP)G:F"N<.%[V%)'!V( M>X5L_72J_YS%&_*GF>Q6-0+BZ;/IW;ZGX<N7W[^?/57;_3 MBA^^[?Q=O9Z;P"/Z$1AI.3.U7$C3#=C8<,=AI6;E%/VD)WNK=-M3;KC9Y34# M+S,(I8X/KKD$W2&D0A74!E@IF.1;7=D2O?%]P+,#F'+W8_8@&28U7M&A#*<8$72-?1%82;"J. M3 W1E6 )[C6*5Z&_&"_8N4T6P_XP*25CAE57L4EPN/8.M/.@0E<+2^*-.5S1!\FT7$0# MT"4 4E(C+"B2"< EXR.X-#!E,'FH$N!HF.0X1)+Z])8I/>? @?/INMJEYU[(YHN# M4D:1Q%>"(2 KH,5N:*4#P_B9(2OAK$!3,JH$R.8N:"1%>8GRN&+(7#HLH*"5 M;9!/A5:X MK->0M"N5U.%%Q7M1Q-P.I43 HW=[P/Z>#<*QP-"@Z:3\BWDHXEQQ,!Z9"#-C M;"7F\'&L _.\R+/2 M_#2:4T%KQJ]Y,V3&,A&>$4>CU^C:.P'=(V02X=!E,-) MC^5HWJ!AK#,UP"D#!KL#\M%'REWTT/;/+N!L/ "M1^A19X!%(95";')G+D.2"6.D$9)M#V_ MA(E37(&64=,,JZIEKS[L&HE M")--2EHMZ.D$H[9):BN=PBP:!1=/@2K;UJ+U-^M03W:@#0I^_XC)%]^EYMS? MJ%5JQ"08T8#8KD 8D"K,#[2RSJ(UXWS>=>\ZL?7R'F*!SS6(\WL'J271?Q.& M910>IZ LJ-B&F$O0W'MD2CO*DU$:2Q%Z(H;+ I+)W"PPT5V,I*O8,R2.YHS% M_1KOWMH_=]Q&^5YJMD8'XG%Q@[GV2EM#3Q!'.]VH3C#;II^3ZD*T01+?VX3\ M +HM30R)[Z.5QO<%@0;G.6*&-#;G$7JSUHRR8#WV$+I&23QK0?KSXG/0!./0 M?=#(SZW(S4L4:Y.MU2P#\^TAWT.8C5M!.Y[>#\B(,7#N#)?R<2M:L4-_KA%% MYU$S8DO#H-. R$(#%DP8&/(\1(NHO%T3"B("A1G(%)+,"5RN5X@.1YS7I#J' MGWB1!C3<#L!FF,.$([@9\('4DS!I]VI><[^D@=-9B"47=CEJ27'LR4OKT=[S M6;6SXTJM_MWFLU("_O$:@GJM&$+)=I-6VF%&II&.'V/_C6-EH*/-']XT!)%B MJ/^IYX'+HLW%4^9J,Y\QNP2ZG$% T;W1C@>H!HIJ;<0'/""GIY6Z\5'2#@JL M%;F.R#P$^>:-O97[1:_56X O?7,PN[GLYDMHM,&71I\>#0R:7R=V);3;%WD0 MVM<$A8HZ6WM V=.7DS4/%=.V(N.VI#O/HY3XO2L3#J13X> /M)R1 ^%R.@ O M7R^E%P=721F@C!4R.^/IC67(FB9A;'RCN&'E;93H8#9K\D1..26;VN"\8#G ,8>)/ MZQ3_'CY5_'NZ[^+?M0MW8W'*N0N]_RK'B/DVKVMRV-MPG6M.2645)?A#,\KE:VY'[\FKFY4,RE,$?9 M+'-X?$D?6W*PEFHF8/A1EUT4K#V_LVG9+.72#=W7UV(74P!)B?GA&*=Q?'QB M-1TV/3VM5T8!3)=_Z'NG0XM>%%J8G-5RZ -&@J[$Z%^%>O5:\U6)UQ;P+;F# M'9IXD)J3S&L:4*+?R%?$1*+C1'GL*$?9U5J.X,]7$2=Z&?I!6M@2?^/=#T_Y MX6_ZLK1^]]/-U?VOO4Y_[V'WW4(..TK/)C4^:P7 V*F7K:IT0H@.;1HJ?9Z& M!\OFB,ID?;&VPN3_T>,<, AKAQA!XD0F06HZ8$0?8JI"3P?$&@F)1W1/)1*_ M7_J^\;>1;?/?5?9>8718"+=> ; MFL.JJI)^P'PLKNGA3\ON_5K;GXB0KS?S HG>R?-MS0P.HV0!E;,2^(X>%O;] M"TM%LE5_GY@',8U+\)\ET+ !P'P $0 &0S-S;S9Z\_'\:M0?_:OS]FWWL/?MKZ]&X\'[7ZHMG HJ$RF7+]WOGX-S&;?[X:G;8V M.LS6QV^Z+[5I"1GIE3EM16J9M7BOFW)9+-U*FTYFD^.#)#L1Q>>%S3(;^T=+ M:[).JO]2QX?UYZ6,=;0]GNM8I>):;<34QA(G#:[&E]>G+:=7:QS5.^OWGI_Q MCW%_].=:+W0FO(/C\AO!/Y_?D+.563MG'N',/2N_,++5_]$LTN2$MGG78C8=GK96+UZ_?G/TBXY7!P>'W=^3%;TP/VU=32XG'L='SSOZ MY0G1##B\#.= AEJ<:9L&6IE B8$Q-LM$S)TTJ##\=B,#@?_]P64@0VCI4+M(PZ:2972BRT3=;2Q3)0>:8#&=&2 M1)HM3 OR5(4"WB9.!3HEO[.U(@C9";.G#*A-.)<1=*H MK5C+5#B5(MVP@DY.<(0U,-C(<34 7C0C!@/>NZ]E: MA!$@@>_:Y.#YKI=T5.W;<"TU"&EX/_E8;,(J-K1LHZ,(.Z4ZS3SQ:&U4IVY6 MI6Y7S!\.,45"&ZR1% 1IF@U5F90JRCPFG@24281TBV+9 N(LV<-2MV7OV);."@@#Q*QFU?#NYA'3KR PYLR'%")U1W*K() MNP$@+CX/IM-)LV'D H8Y&^DXYYQ-\2O>R&/*.J0RUA?)/9\-#]D _'*$I3( M6%@!L^(\\UG?IOAN%$>GM(@65.&_O^7-"(DCNS5SZ@SC 'Y+45'!$[[<@5+ M%9D9.+GDHVWN<) #5@@DF[>LT@Z@X>%JRX_'(K+VML2DV2@SIH MW.4/.T%? MA7F0$?J[A #ZB%-!AS9%Z\V)0"HA&V2$XC64::8B!2/?+K=1X?B%6]WL-E8=UMG&O-MP6YP.94&O869Y?E89!)%QW" 8IUR M/Z%$]CRD+ST'Z1#E(?7./%JB5M(^MZ!F MC0E!89.B61=Y539Q4 'KD1S@YI9B5F=<&Y5ZD*X54%3MW@12\EN-N\4W7N MTL%EVA+,BUQ'(6&.G3]V9]W:#E_<=[9'MP\1XI1Y0-G*^U"GOY@(A.?R$]K7 MKIQ! 8KXG=5#;?F1RN DU Y5,0MN(.Q&_./5T8&'.2;T++H#LZ!(88TR$/R1 MZX)6*-"_RK_^VC>E#!JCL<;+T%5WVN8I- ,7P[!LAN0-=D:A2-47NU3M]<&# M!U&DW$JBIV^@U7".*O?&Z75'\^'EV)6ETH/A2^8JL@N&NRAT>-9L['2,KS:] M-T]!>Q+EE(@>]3WQ4>R@@3CDA3NR,F;Z:CX7@VGER+0[J$W7!:'WG[.G)E M+/<=P*:Y#"%<';H*&"K8F:/R5-Z=>A>3ZWDUBUCK3'72!#0\-G8#?K3ZVO T M /L:^:/.X^CD#ME";\'U&K@=44?*URTLT:XW[K.HHS$","\^'O''>_+N'J_> M4Y74IF*K\)3?K[6[>C/1"0)E%"?8G=21C[*IQ<1&+5#34(PRGF5\[&\VFZ[$ M-\B]+FC:>_Z1)QU%@S &5/%,@FJU!B\ATA_[7J8G!"+Q7;7FESJ\*Q M*5=4+'E^/OX-3XH14+,A^'\O0:?81NH^>53\!7?H48):T5F ^;>=A0(\ZEA& M2,Z49AR]=U,Q&_\;47S1*K?D$=3QL[?\KR4^C<_G[TY;AP<'/U0CB^'H>CZ: M_M_-IPC8H0+GX:2H'UC)5G<%5>"&ZIK '&&?NV\_+S"CY5/ ML"FQ*1:#@,OIX=NW+[L5R ]X4(B_QYW:R]1R9@ QJ=4RK>Z807&G.\$3%"R= M<'%;YEGN2LEWPOLEB#]6^+Y8-119 E'(_-)U7Z:K,EBJ>XK[K4)P=X_>,7SG MDH$VP-6'U,O20@%O2L\>' &#YB4V\!W*5\[=?;[XEO *4+29 MP+O%G!6S6J$'\_6@$A7W(UW.FKB9A=BD& ]X.\GA&OU0X:J0EM<##H/Q Q=< M)0VD:U0=3%&(5,FLRC[NFEYO/7RP)RIAZ+,VI_X%6&D2%T+5$,"*.AZ1#KO0 MB$LHQ)02-X;"L@'2I#8QIS?(@AW"PZEVI9IU,:S)5)K5=UU/11]*%"=9S/] M,;1$6UZ""OPUV)%(Y\=WWWKH-*AA>X1I'CA/]T#F1"C.A&8#= ,.*BVHX?." MAE!?20JNR0K!E,6(BW#]6DZPZ"ANM0@#%>,RCS_D0$DY[#]5=(,G97%!%?-O MY=/A0>=#(9=P'XJP];6]XP&DOX>\Y;'[D9\:JRA5_I)%!-\UP/&QWG]+TEV$ MN!AXPQFU2BGR(6UB&(\PZ6.[SK?9:%A A/#PE8]^\M2B4DW8C;01M')W9>^^ M S&BB(?_CW<;HNI^QZ5PE7W%&A+ZY5!=A-3H"$:Z&IB0ID6!2C+!(W_<;5TQ M\DR2"-E++D=R4\PX>3R=R5N8:*RPBZALD<"*+M]]&UL4$L! A0#% @ VT-C5L5=SN.\! -BP !4 M ( !%PH &%A9&DM,C R,S S,#)?<')E+GAM;%!+ 0(4 Q0 ( M -M#8U9>3N%2CA, !5Z . " 08/ !D,S